Lamotrigine: how effective is it as add-on therapy in Bulgarian patients with drug-resistant epilepsy
Department of Neurology, Medical University – Plovdiv, Bulgaria UMHAT St. George, Plovdiv, Bulgaria.
Research Article
GSC Biological and Pharmaceutical Sciences, 2019, 08(03), 109-121.
Article DOI: 10.30574/gscbps.2019.8.3.0164
Publication history:
Received on 30 August 2019; revised on 14 September 2019; accepted on 20 September 2019
Abstract:
The study purpose was to perform an open, prospective study on various aspects of Lamotrigine (LTG) effectiveness in Bulgarian patients with drug-resistant epilepsy. The study was performed with the participation of patients with epilepsy who attended the Clinic of Neurology at the University Hospital in Plovdiv, Bulgaria. The patients completed diaries about seizure frequency, severity, and adverse events. There were regular documented visits at 3 or 6 months during the first year of treatment with LTG and at 6 months afterwards, with dynamic assessment of seizure frequency, severity, adverse events, and EEG recordings. LTG was applied as add-on treatment in 73 patients (47 males, mean age 36 years). There was a relatively mild and stable dynamic improvement of seizure severity, a satisfactory seizure frequency reduction in 39.7% of participants, a stable mean seizure frequency reduction (43-59%) from the 6th to the 36th month of treatment and a stable responder rate (55.7-59.4%) during the same period. There were adverse events (dizziness/vertigo, generalized edema, irritability, aggressiveness, speech disturbances, visual hallucinations, sleepiness, insomnia, headache, diplopia, nystagmus, impaired balance, muscle cramps, gastrointestinal discomfort, generalized rash, fatigue, nausea) in 12.3% of patients. In conclusion, LTG treatment is associated with: a low and stable improvement of seizure severity, a good and stable improvement of seizure frequency, a possible worsening of seizure control, a good safety and tolerability.
Keywords:
Lamotrigine; Epilepsy; Efficacy; Tolerability; Adverse events
Full text article in PDF:
Copyright information:
Copyright © 2019 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
